Literature DB >> 17186389

Effect of rebamipide on the colonic barrier in interleukin-10-deficient mice.

David Laharie1, Sandrine Ménard, Corinne Asencio, Teresita Vidal-Martinez, Anne Rullier, Frank Zerbib, Céline Candalh, Francis Mégraud, Martine Heyman, Tamara Matysiak-Budnik.   

Abstract

Our aim was to study the effect of a mucosal protective agent, rebamipide, on the colonic barrier and the immune response in colitis-prone interleukin-10-deficient (IL-10-/-) C57BL/6 mice infected with Helicobacter hepaticus. After sacrifice, in all mice, control, or previously infected with H. hepaticus, or previously infected and treated with rebamipide enema, a histological examination of colonic samples was performed, intestinal permeability was studied in Ussing chamber, and mesenteric lymph node proliferation and cytokine secretion were measured. Mice treated with rebamipide presented a reinforcement of the distal colonic epithelial barrier, an increase of mesenteric lymph node cells proliferation, and of IFNgamma and IL-12 secretion. These results indicate that in IL-10-/- mice with mild colitis, rectally administered rebamipide reinforces the distal colonic barrier and has a slight Th1 immuno-stimulatory effect on mesenteric lymph node cells. These properties could be helpful in the management of some inflammatory bowel diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17186389     DOI: 10.1007/s10620-006-9183-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  39 in total

1.  The assay of catalases and peroxidases.

Authors:  A C MAEHLY; B CHANCE
Journal:  Methods Biochem Anal       Date:  1954

2.  Alterations of epithelial permeability by Helicobacter and IL-1beta in vitro: protective effect of rebamipide.

Authors:  T Matysiak-Budnik; A Thomas-Collignon; F Mégraud; M Heyman
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

3.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.

Authors:  D J Berg; N Davidson; R Kühn; W Müller; S Menon; G Holland; L Thompson-Snipes; M W Leach; D Rennick
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

4.  Positive effect of rebamipide on gastric permeability in mice after eradication of Helicobacter felis.

Authors:  T Matysiak-Budnik; A de Mascarel; M Abely; K Mayo; M Heyman; F Mégraud
Journal:  Scand J Gastroenterol       Date:  2000-05       Impact factor: 2.423

5.  Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease.

Authors:  J D Söderholm; G Olaison; K H Peterson; L E Franzén; T Lindmark; M Wirén; C Tagesson; R Sjödahl
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

6.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

Authors:  Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

7.  Gastric Helicobacter infection inhibits development of oral tolerance to food antigens in mice.

Authors:  Tamara Matysiak-Budnik; Guillaume van Niel; Francis Mégraud; Kathryn Mayo; Claudia Bevilacqua; Valérie Gaboriau-Routhiau; Marie-Christiane Moreau; Martine Heyman
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

8.  Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat.

Authors:  K Yamasaki; T Kanbe; T Chijiwa; H Ishiyama; S Morita
Journal:  Eur J Pharmacol       Date:  1987-10-06       Impact factor: 4.432

9.  IFN-gamma-induced iNOS mRNA expression is inhibited by rebamipide in murine macrophage RAW264.7 cells.

Authors:  C Nagano; H Wakebe; A Azuma; K Imagawa; M Kikuchi
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

10.  Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance.

Authors:  J McCarthy; L O'Mahony; L O'Callaghan; B Sheil; E E Vaughan; N Fitzsimons; J Fitzgibbon; G C O'Sullivan; B Kiely; J K Collins; F Shanahan
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more
  5 in total

Review 1.  Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad.

Authors:  Maciej Chichlowski; Laura P Hale
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-10-16       Impact factor: 4.052

Review 2.  Effects of Helicobacter infection on research: the case for eradication of Helicobacter from rodent research colonies.

Authors:  Maciej Chichlowski; Laura P Hale
Journal:  Comp Med       Date:  2009-02       Impact factor: 0.982

3.  Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study.

Authors:  Yasumasa Niwa; Masanao Nakamura; Naoki Ohmiya; Osamu Maeda; Takafumi Ando; Akihiro Itoh; Yoshiki Hirooka; Hidemi Goto
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

4.  A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury.

Authors:  Sei Kurokawa; Shinichi Katsuki; Tomoki Fujita; Yusuke Saitoh; Hidetoshi Ohta; Kouji Nishikawa; Yasushi Sato; Yasuhiro Sato; Koji Ohira; Masataka Yamada; Mototsugu Kato
Journal:  J Gastroenterol       Date:  2013-04-18       Impact factor: 7.527

5.  Curcumin protects intestinal mucosal barrier function of rat enteritis via activation of MKP-1 and attenuation of p38 and NF-κB activation.

Authors:  Wei-Bing Song; Yuan-Yuan Wang; Fan-Su Meng; Qing-Hua Zhang; Jian-Ying Zeng; Li-Ping Xiao; Xin-Pei Yu; Dan-dan Peng; Lei Su; Bing Xiao; Zhen-Shu Zhang
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.